NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

This is total and utter nonsense.

1) It's a CDMO with a completely specific and defined role that has been the same since the very beginning of the trial. The only difference is that the CEO's private equity company had started the first manufacturer, and shorts messed up their relationship and that company, much larger, needed to be sold to Charles River Laboratories, but she had, with those entrepreneurs, created a totally unique kind of manufacturing entity, one that CRL found was worth buying and establishing because of this new area of CDMO work.

2) To preserve the expertise developed in manufacturing DCVax-L, she was able to get the UK entity spun out to her PE, to 1) keep the local license for manufacturing, and 2) further develop Sawston's capabilities.

3) The relationship is fundamentally the same as with any start-up bio and CDMO and there are requirements that they maintain it as such, including a policy created to address this very issue in response to a previous complaint by shorts to the SEC. There is no stealing or theft or nonsense going on and this has NEVER been a real thing, just a bogey man used to manipulate anyone ignorant enough to believe it.

4) NWBO owns Flaskworks outright and that is the future of production. The current handmade production, which was done during the trials first by their previous manufacturer and now by that subsidiary that was spun of, Advent, will no longer be the primary production mode, they expect. But so long as it persists, it keeps the operational risks and costs at a separate entity, something that helps them avoid Dendreon's fate. And that drives SHORTS nuts as well, because they were hoping for another dendron.

5) The other brilliant move by the CEO was to get local, regional financing for the manufacturing operation, and because Advent had no real manufacturing facility other than NWBO's Sawston facility, they could do a deal where "NWBO", but really Advent, agreed to provide local businesses in the Cambridge University area, access to the specialized research and trial capabilities that having access to such a manufacturer would provide. So the relationship effectively became symbiotic, and a portion of Sawston is effectively a locally financed development facility for this kind of technology. That situates both companies in a great, local role to find different kinds of research partners and innovate as well and it subsidizes, potentially, Sawston, so long as it is not engaged in commercial operations for NWBO. Lastly, having a CDMO isolates the costs and risks of all of those employees, their retirement benefits and other aspects of early growth, which is not a minor consideration. It's a win, win, win all around.